QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
NASDAQ:RARE

Ultragenyx Pharmaceutical (RARE) Stock Forecast, Price & News

$36.67
+0.24 (+0.66%)
(As of 09/25/2023 ET)
Compare
Today's Range
$35.57
▼
$37.27
50-Day Range
$34.92
▼
$44.21
52-Week Range
$33.36
▼
$54.98
Volume
713,493 shs
Average Volume
613,521 shs
Market Capitalization
$2.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$81.21
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Ultragenyx Pharmaceutical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.82 Rating Score
Upside/​Downside
121.5% Upside
$81.21 Price Target
Short Interest
Bearish
5.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.28
Upright™ Environmental Score
News Sentiment
0.77mentions of Ultragenyx Pharmaceutical in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$379,400 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($8.65) to ($7.11) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

282nd out of 961 stocks

Pharmaceutical Preparations Industry

115th out of 455 stocks

See Top Rated MarketRank™ Stocks Here

RARE stock logo

About Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

RARE Price History

RARE Stock News Headlines

September 25, 2023 | marketwatch.com
Ultragenyx Says the Cholesterol Evkeeza Gets Canadian Approval
September 22, 2023 | americanbankingnews.com
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Rating of "Moderate Buy" by Brokerages
September 25, 2023 | Stansberry Research (Ad)
Are "The Magnificent Seven" the Next Sears?
The former retail giant’s sales once accounted for 1% of the U.S. economy. Now it’s nearly extinct. Will the same happen to big tech? Learn more here.
September 21, 2023 | tmcnet.com
Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
September 10, 2023 | fool.com
Ultragenyx Pharmaceutical (NASDAQ: RARE)
September 7, 2023 | finance.yahoo.com
Is Ultragenyx Pharmaceutical (RARE) Too Good to Be True? A Comprehensive Analysis of a ...
August 31, 2023 | finance.yahoo.com
Ultragenyx to Participate at Investor Conferences in September
August 30, 2023 | msn.com
Ultragenyx: Market Expectations Revised Lower, Awaiting Clinical Trial Catalysts (Rating Downgrade)
September 25, 2023 | Stansberry Research (Ad)
Are "The Magnificent Seven" the Next Sears?
The former retail giant’s sales once accounted for 1% of the U.S. economy. Now it’s nearly extinct. Will the same happen to big tech? Learn more here.
August 14, 2023 | bizjournals.com
Estate of Henrietta Lacks, whose immortal cell line has fueled medical research, sues drug developer Ultragenyx
August 11, 2023 | msn.com
Novato's Ultragenyx 'Unjustly' Profited From Stolen Cells: Lawsuit
August 11, 2023 | msn.com
Henrietta Lacks family files suit against another pharmaceutical company
August 11, 2023 | msn.com
Family of Henrietta Lacks sues pharmaceutical company days after settlement with biotech giant
August 11, 2023 | finance.yahoo.com
Henrietta Lacks' family sues Ultragenyx over use of HeLa cell line
August 8, 2023 | finance.yahoo.com
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 41% Below Their Intrinsic Value Estimate
August 6, 2023 | markets.businessinsider.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Cigna (CI) and Ultragenyx Pharmaceutical (RARE)
August 5, 2023 | msn.com
Morgan Stanley Reiterates Ultragenyx Pharmaceutical (RARE) Overweight Recommendation
August 4, 2023 | finance.yahoo.com
Q2 2023 Ultragenyx Pharmaceutical Inc Earnings Call
August 4, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN), Ultragenyx Pharmaceutical (RARE) and AmerisourceBergen (ABC)
August 3, 2023 | markets.businessinsider.com
Ultragenyx Pharmaceutical Inc Q2 Loss misses estimates
August 3, 2023 | finance.yahoo.com
Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update
July 31, 2023 | finance.yahoo.com
Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
July 27, 2023 | finance.yahoo.com
Ultragenyx to Host Conference Call for Second Quarter 2023 Financial Results and Corporate Update
July 15, 2023 | finanznachrichten.de
Ultragenyx Pharmaceutical Inc.: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 12, 2023 | finanznachrichten.de
Ultragenyx Pharmaceutical Inc.: Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy
July 12, 2023 | finance.yahoo.com
Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy
July 6, 2023 | finance.yahoo.com
Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
See More Headlines
Receive RARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

RARE Company Calendar

Last Earnings
8/03/2023
Today
9/25/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RARE
CUSIP
N/A
CIK
1515673
Web
www.ultragenyx.com
Phone
(415) 483-8800
Fax
415-483-8810
Employees
1,311
Year Founded
2010

Price Target and Rating

Average Stock Price Forecast
$81.21
High Stock Price Forecast
$133.00
Low Stock Price Forecast
$47.00
Forecasted Upside/Downside
+127.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
11 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($10.24)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-707,420,000.00
Net Margins
-178.91%
Pretax Margin
-177.40%
Return on Equity
-220.54%
Return on Assets
-44.07%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.87
Quick Ratio
2.76

Sales & Book Value

Annual Sales
$363.33 million
Price / Sales
7.02
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.03 per share
Price / Book
7.10

Miscellaneous

Outstanding Shares
71,500,000
Free Float
66,638,000
Market Cap
$2.55 billion
Optionable
Optionable
Beta
0.87

Social Links

A Guide To High-Short-Interest Stocks Cover
A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Emil D. Kakkis M.D. (Age 63)
    Ph.D., Founder, Pres, CEO & Director
    Comp: $1.37M
  • Mr. John Richard Pinion IIMr. John Richard Pinion II (Age 57)
    Chief Quality Operations Officer & Exec. VP of Translational Sciences
    Comp: $806.19k
  • Mr. Erik HarrisMr. Erik Harris (Age 52)
    Exec. VP & Chief Commercial Officer
    Comp: $848.24k
  • Mr. Theodore A. HuizengaMr. Theodore A. Huizenga (Age 52)
    Sr. VP, Corp. Controller & Principal Accounting Officer
  • Mr. Dennis Karl HuangMr. Dennis Karl Huang (Age 58)
    Chief Technical Operations Officer & Gene Therapy Operations and Exec. VP
  • Ms. Danielle Keatley
    Sr. Director of Investor Relations & Corp. Communications
  • Ms. Karah Herdman Parschauer J.D.Ms. Karah Herdman Parschauer J.D. (Age 45)
    Chief Legal Officer & Exec. VP
  • Mr. Ernie W. Meyer (Age 59)
    Chief HR Officer & Exec. VP
  • Mr. Thomas R. Kassberg (Age 63)
    Chief Bus. Officer & Exec. VP
  • Mr. Vimal Srivastava (Age 58)
    Sr. VP of Bus. Devel. & Alliance Management

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













RARE Stock - Frequently Asked Questions

Should I buy or sell Ultragenyx Pharmaceutical stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RARE shares.
View RARE analyst ratings or view top-rated stocks.

What is Ultragenyx Pharmaceutical's stock price forecast for 2023?

11 brokers have issued 1-year target prices for Ultragenyx Pharmaceutical's stock. Their RARE share price forecasts range from $47.00 to $133.00. On average, they predict the company's stock price to reach $81.21 in the next twelve months. This suggests a possible upside of 121.5% from the stock's current price.
View analysts price targets for RARE or view top-rated stocks among Wall Street analysts.

How have RARE shares performed in 2023?

Ultragenyx Pharmaceutical's stock was trading at $46.33 on January 1st, 2023. Since then, RARE shares have decreased by 20.9% and is now trading at $36.67.
View the best growth stocks for 2023 here.

When is Ultragenyx Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our RARE earnings forecast.

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) issued its quarterly earnings results on Thursday, August, 3rd. The biopharmaceutical company reported ($2.25) earnings per share for the quarter, missing analysts' consensus estimates of ($2.11) by $0.14. The biopharmaceutical company earned $108.30 million during the quarter, compared to analyst estimates of $107.10 million. Ultragenyx Pharmaceutical had a negative net margin of 178.91% and a negative trailing twelve-month return on equity of 220.54%. The company's quarterly revenue was up 21.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($2.26) EPS.

What ETFs hold Ultragenyx Pharmaceutical's stock?

ETFs with the largest weight of Ultragenyx Pharmaceutical (NASDAQ:RARE) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), Virtus LifeSci Biotech Products ETF (BBP), Motley Fool Small-Cap Growth ETF (TMFS), Motley Fool Mid-Cap Growth ETF (TMFM), MFAM Small-Cap Growth ETF (MFMS), WisdomTree BioRevolution Fund (WDNA) and SPDR S&P Biotech ETF (XBI).

What guidance has Ultragenyx Pharmaceutical issued on next quarter's earnings?

Ultragenyx Pharmaceutical issued an update on its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $425.00 million-$450.00 million, compared to the consensus revenue estimate of $437.55 million.

What is Emil D. Kakkis' approval rating as Ultragenyx Pharmaceutical's CEO?

41 employees have rated Ultragenyx Pharmaceutical Chief Executive Officer Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Ultragenyx Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM).

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Who are Ultragenyx Pharmaceutical's major shareholders?

Ultragenyx Pharmaceutical's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.09%), Clearbridge Investments LLC (3.87%), Sands Capital Management LLC (3.74%), State Street Corp (3.45%), Alliancebernstein L.P. (2.12%) and Rock Springs Capital Management LP (1.94%). Insiders that own company stock include Camille L Bedrosian, Camille L Bedrosian, Corazon (Corsee) D Sanders, Dennis Karl Huang, Emil D Kakkis, Emil D Kakkis, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, S Robson Walton, Theodore Alan Huizenga, Thomas Richard Kassberg and William Aliski.
View institutional ownership trends.

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ultragenyx Pharmaceutical's stock price today?

One share of RARE stock can currently be purchased for approximately $36.67.

How much money does Ultragenyx Pharmaceutical make?

Ultragenyx Pharmaceutical (NASDAQ:RARE) has a market capitalization of $2.62 billion and generates $363.33 million in revenue each year. The biopharmaceutical company earns $-707,420,000.00 in net income (profit) each year or ($10.24) on an earnings per share basis.

How many employees does Ultragenyx Pharmaceutical have?

The company employs 1,311 workers across the globe.

How can I contact Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The official website for the company is www.ultragenyx.com. The biopharmaceutical company can be reached via phone at (415) 483-8800, via email at ir@ultragenyx.com, or via fax at 415-483-8810.

This page (NASDAQ:RARE) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -